Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hazem A Mahdy

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Drug Development Research|May 3, 2026
Structure-Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors With Potent Anticancer ActivityHazem Elkady, Walid E Elgammal, Ibrahim H Eissa, et al.
Future Medicinal Chemistry|June 16, 2026
Thiazolidin-based dual Aurora kinase inhibitors with potent anticancer activityWalid E Elgammal, Hazem Elkady, Aisha A Alsfouk, et al.
Future Medicinal Chemistry|April 8, 2025
Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitorsWalid E Elgammal, Hazem Elkady, Mohammed A Dahab, et al.
Archiv Der Pharmazie|December 4, 2021
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studiesNawaf A Alsaif, Hazem A Mahdy, Mohammed M Alanazi, et al.
Bioorganic Chemistry|May 23, 2021
New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluationMohammed M Alanazi, Hazem A Mahdy, Nawaf A Alsaif, et al.
Bioorganic Chemistry|May 28, 2026
New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activityBshra A Alsfouk, Hazem Elkady, Walid E Elgammal, et al.
Future Medicinal Chemistry|August 29, 2025
Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis inductionEslam B Elkaeed, Walid E Elgammal, Hazem Elkady, et al.
RSC Advances|December 20, 2023
Rationale design and synthesis of new apoptotic thiadiazole derivatives targeting VEGFR-2: computational and <i>in vitro</i> studiesWalid E Elgammal, Hazem Elkady, Hazem A Mahdy, et al.
Archiv Der Pharmazie|September 29, 2025
New 1,3,4-Thiadiazole-Based Dual B-Raf/VEGFR-2 Inhibitors With Potential Anti-Breast Activity: Design, Synthesis, In Vitro and In Silico EvaluationsWalid E Elgammal, Hazem Elkady, Hazem A Mahdy, et al.
Archiv Der Pharmazie|July 1, 2025
Development of New Thiadiazole Derivatives as VEGFR-2 Inhibitors With Anticancer and Proapoptotic Activities‏Hazem Elkady, Walid E Elgammal, Mohamed M Khalifa, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Drug Development Research|May 3, 2026
Structure-Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors With Potent Anticancer ActivityHazem Elkady, Walid E Elgammal, Ibrahim H Eissa, et al.
Future Medicinal Chemistry|June 16, 2026
Thiazolidin-based dual Aurora kinase inhibitors with potent anticancer activityWalid E Elgammal, Hazem Elkady, Aisha A Alsfouk, et al.
Future Medicinal Chemistry|April 8, 2025
Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitorsWalid E Elgammal, Hazem Elkady, Mohammed A Dahab, et al.
Archiv Der Pharmazie|December 4, 2021
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studiesNawaf A Alsaif, Hazem A Mahdy, Mohammed M Alanazi, et al.
Bioorganic Chemistry|May 23, 2021
New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluationMohammed M Alanazi, Hazem A Mahdy, Nawaf A Alsaif, et al.
Bioorganic Chemistry|May 28, 2026
New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activityBshra A Alsfouk, Hazem Elkady, Walid E Elgammal, et al.
Future Medicinal Chemistry|August 29, 2025
Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis inductionEslam B Elkaeed, Walid E Elgammal, Hazem Elkady, et al.
RSC Advances|December 20, 2023
Rationale design and synthesis of new apoptotic thiadiazole derivatives targeting VEGFR-2: computational and <i>in vitro</i> studiesWalid E Elgammal, Hazem Elkady, Hazem A Mahdy, et al.
Archiv Der Pharmazie|September 29, 2025
New 1,3,4-Thiadiazole-Based Dual B-Raf/VEGFR-2 Inhibitors With Potential Anti-Breast Activity: Design, Synthesis, In Vitro and In Silico EvaluationsWalid E Elgammal, Hazem Elkady, Hazem A Mahdy, et al.
Archiv Der Pharmazie|July 1, 2025
Development of New Thiadiazole Derivatives as VEGFR-2 Inhibitors With Anticancer and Proapoptotic Activities‏Hazem Elkady, Walid E Elgammal, Mohamed M Khalifa, et al.
Pageof 5